3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma, Non-Hodgkin
3
Recurrence
2
Melanoma
2
Lymphoma, Large B-Cell, Diffuse
2
Hodgkin Disease
2
Various Advanced Cancer
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Gastroesophageal Cancer
1
Fallopian Tube Neoplasms
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Advanced Cancer
1
Interventions
Sorafenib
7
Radiosurgery
6
Bevacizumab
6
pembrolizumab
4
Oxaliplatin
4
Cryosurgery
4
atezolizumab
3
Radiotherapy, Conformal
3
Nivolumab
3
Ipilimumab
3
Fluorouracil
3
Cyclophosphamide
3
tremelimumab
2
spartalizumab
2
lenvatinib
2
fludarabine
2
Leucovorin
2
Injections
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Doxorubicin
2
Celecoxib
2
Carboplatin
2
Capecitabine
2
yttrium chloride
1
vofatamab
1
toripalimab
1
tocilizumab
1
sapanisertib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Liver Neoplasms
×
relatlimab
×
Clear all
NCT05337137
2026-01-12
RELATIVITY-106
Bristol-Myers Squibb
Phase 1/2
Completed
83 enrolled